CN121844044A - Bcl11a基因的增强子的一部分或全部被破坏了的造血干细胞的制造方法、和用于该方法的试剂盒 - Google Patents

Bcl11a基因的增强子的一部分或全部被破坏了的造血干细胞的制造方法、和用于该方法的试剂盒

Info

Publication number
CN121844044A
CN121844044A CN202480058255.5A CN202480058255A CN121844044A CN 121844044 A CN121844044 A CN 121844044A CN 202480058255 A CN202480058255 A CN 202480058255A CN 121844044 A CN121844044 A CN 121844044A
Authority
CN
China
Prior art keywords
protein
enhancer
crispr
cas3
hematopoietic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480058255.5A
Other languages
English (en)
Chinese (zh)
Inventor
小堀峻吾
佐伯凉太
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
C4u Corp
Original Assignee
C4u Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C4u Corp filed Critical C4u Corp
Publication of CN121844044A publication Critical patent/CN121844044A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202480058255.5A 2023-10-30 2024-10-29 Bcl11a基因的增强子的一部分或全部被破坏了的造血干细胞的制造方法、和用于该方法的试剂盒 Pending CN121844044A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023185785 2023-10-30
JP2023-185785 2023-10-30
PCT/JP2024/038444 WO2025094917A1 (ja) 2023-10-30 2024-10-29 Ｂｃｌ１１ａ遺伝子のエンハンサーの一部又は全部が破壊された造血幹細胞の製造方法、及びその方法に用いるためのキット

Publications (1)

Publication Number Publication Date
CN121844044A true CN121844044A (zh) 2026-04-10

Family

ID=95582304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480058255.5A Pending CN121844044A (zh) 2023-10-30 2024-10-29 Bcl11a基因的增强子的一部分或全部被破坏了的造血干细胞的制造方法、和用于该方法的试剂盒

Country Status (3)

Country Link
JP (1) JPWO2025094917A1 (https=)
CN (1) CN121844044A (https=)
WO (1) WO2025094917A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109554350B (zh) 2012-11-27 2022-09-23 儿童医疗中心有限公司 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件
AU2017252023B2 (en) * 2016-04-18 2024-05-02 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
DK3636753T5 (da) 2017-06-08 2024-08-26 Univ Osaka Fremgangsmåde til fremstilling af DNA-redigeret eukaryotisk celle
AU2018378479B2 (en) 2017-12-05 2025-03-13 Vertex Pharmaceuticals Incorporated CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
WO2020184723A1 (ja) * 2019-03-14 2020-09-17 国立大学法人徳島大学 Ｃｒｉｓｐｒタイプｉ－ｄシステムを利用した標的配列改変技術
JP2022547105A (ja) * 2019-09-04 2022-11-10 博雅▲輯▼因（北京）生物科技有限公司 オフターゲット評価に基づく遺伝子編集治療の評価方法
KR20230150998A (ko) * 2021-03-01 2023-10-31 씨포유 가부시키가이샤 Cas3 단백질을 제조하는 방법

Also Published As

Publication number Publication date
JPWO2025094917A1 (https=) 2025-05-08
WO2025094917A1 (ja) 2025-05-08

Similar Documents

Publication Publication Date Title
US12529051B2 (en) Methods of treating amyotrophic lateral sclerosis (ALS)
JP2022549120A (ja) 標的ゲノム修飾のための高度に効率的なｒｎａ－アプタマー動員媒介性ｄｎａ塩基エディターおよびそれらの使用
JP2019500043A (ja) 異常ヘモグロビン症の治療用組成物および方法
CN107532168A (zh) 治疗血红蛋白病的材料和方法
JP2021521855A (ja) ヘモグロビン関連変異の編集のための相同組換え修復用鋳型の設計およびその送達
WO2002097090A1 (en) Genes with es cell-specific expression
CN108823202A (zh) 用于特异性修复人hbb基因突变的碱基编辑系统、方法、试剂盒及其应用
US20210032612A1 (en) CRISPR/Cas9 Systems, and Methods of Use Thereof
WO2022225978A1 (en) Use of a split dcas fusion protein system for epigenetic editing
CN114245803A (zh) 用于重构小神经胶质细胞的方法和组合物
US20160045575A1 (en) FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION AND RELATED cDNAs, COMPOSITIONS, METHODS AND SYSTEMS
WO2023055893A1 (en) Gene regulation
EP4079765A1 (en) Fusion protein that improves gene editing efficiency and application thereof
CN114752629A (zh) 一种针对细胞中单个或多个基因进行基因编辑的方法、产品和应用
US20250163410A1 (en) Crispr-transposon systems for dna modification
CN110551761A (zh) CRISPR/Sa-SepCas9基因编辑系统及其应用
CN114364799A (zh) 编辑造血干/祖细胞中bcl11a基因的方法
CN121844044A (zh) Bcl11a基因的增强子的一部分或全部被破坏了的造血干细胞的制造方法、和用于该方法的试剂盒
EP3901262A1 (en) Compositions for use in treating autosomal dominant best1-related retinopathies
WO2020225754A1 (en) Crispr gene editing for autosomal dominant diseases
CN110499334A (zh) CRISPR/SlugCas9基因编辑系统及其应用
CN112218945A (zh) 纯合细胞的制作方法
US20220056440A1 (en) Crispr gene editing for autosomal dominant diseases
CN116355958A (zh) 改善人细胞中was蛋白表达的方法
CN110551763B (zh) CRISPR/SlutCas9基因编辑系统及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination